Armistice Capital, LLC and Steven Boyd filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 1,542,681 shares of Lantern Pharma Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: 1,542,681 shares of Lantern Pharma Inc. common stock, representing 9.99% of the class.
  • Shared voting and dispositive power: Both Armistice Capital, LLC and Steven Boyd report shared voting power and shared dispositive power over all 1,542,681 shares; sole voting and sole dispositive power are each reported as 0.
  • Direct holder: The shares are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company and investment advisory client of Armistice Capital.
  • Reporting persons: Armistice Capital, LLC (Delaware, classified as investment adviser and other) and Steven Boyd (United States, classified as holding company and individual).
  • Triggering event date: The event requiring the filing occurred on September 30, 2026.

Armistice Capital and Steven Boyd Disclose Lantern Pharma Position

According to the Schedule 13G filed on November 16, 2026, Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 1,542,681 shares of Lantern Pharma Inc. (NASDAQ:LTRN) common stock, par value $0.0001 per share (CUSIP: 51654W101). The filing states that this position represents 9.99% of the class, based on the event date of September 30, 2026.

The filing discloses that Armistice Capital, LLC serves as the investment manager of Armistice Capital Master Fund Ltd., which is the direct holder of the shares. "Pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund," according to the filing. Steven Boyd, as the managing member of Armistice Capital, LLC, is also deemed to beneficially own the same shares through that structure.

The filing further states that "the Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital." The filing also notes that the Master Fund has the right to receive dividends from, or the proceeds from the sale of, the reported securities. The certification included in the filing states that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

Armistice Capital, LLC and Steven Boyd filed a Schedule 13G disclosing 1,542,681 shares, or 9.99%, of Lantern Pharma Inc. common stock beneficially owned as of September 30, 2026, with all voting and dispositive power held on a shared basis through the Master Fund structure.